Humacyte, Inc. (HUMA): Price and Financial Metrics
GET POWR RATINGS... FREE!
HUMA Stock Price Chart Interactive Chart >
HUMA Price/Volume Stats
| Current price | $5.50 | 52-week high | $17.45 |
| Prev. close | $5.11 | 52-week low | $4.26 |
| Day low | $4.94 | Volume | 306,700 |
| Day high | $5.61 | Avg. volume | 408,376 |
| 50-day MA | $6.37 | Dividend yield | N/A |
| 200-day MA | $8.39 | Market Cap | 566.53M |
Humacyte, Inc. (HUMA) Company Bio
Humacyte, Inc., a clinical-stage biotechnology platform company, develops and manufactures off-the-shelf bioengineered human tissues. The company develops and manufactures acellular tissues to address life- and limb-threatening vascular conditions for complex organ disease. Its Human Acellular Vessel (HAV), a regenerative vascular conduit that is in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. The company was founded in 2004 and is based in Durham, North Carolina.
Latest HUMA News From Around the Web
Below are the latest news stories about Humacyte Inc that investors may wish to consider to help them evaluate HUMA as an investment opportunity.
Humacyte to Participate in Fireside Chat at BTIG MedTech, Digital Health, Life Science & Diagnostic Tools ConferenceDURHAM, N.C., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, and Dale Sander, Chief Financial Officer, will participate in a virtual fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on Feb. 15, 2022, at 9 a.m. EST. The webcast will |
Humacyte Announces Clinical Case Series Demonstrating Potential of Human Acellular Vessel™ (HAV™) to Expand Opportunities for Limb Salvage in Multiple Complex Vascular Reconstruction Scenarios– Outcomes of first eight compassionate use cases presented at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society – – HAV observed to maintain patency and resist infection in the treatment of critical limb ischemia, infection and vascular trauma – – All patients lacked suitable alternative conduit options – DURHAM, N.C., Jan. 31, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioe |
Humacyte Announces Preclinical Results of Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting-- HAV remained patent and host-cell remodeling was observed in non-human primate model -- -- Preclinical study represents milestone in the development of small-diameter HAVs for use in cardiac bypass surgery -- -- Results presented at Advanced Therapies Week 2022 -- DURHAM, N.C., Jan. 28, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced result |
Humacyte (NASDAQ:HUMA) shareholders have endured a 47% loss from investing in the stock a year agoThe simplest way to benefit from a rising market is to buy an index fund. When you buy individual stocks, you can make... |
Humacyte Announces Presentation of First Eight Expanded Access Cases Using Human Acellular Vessel™ (HAV) for Treatment of Critical Limb Ischemia at 46th Annual Winter Meeting of the Vascular and Endovascular Surgery SocietyDURHAM, N.C., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that results from the first series of compassionate use cases of Humacyte’s Human Acellular VesselTM (HAV) will be presented at the 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society (VESS) in Snowmass, Colo. at 7:56 a.m. MST on January 28, 2022. Th |
HUMA Price Returns
| 1-mo | -22.32% |
| 3-mo | -8.79% |
| 6-mo | -49.22% |
| 1-year | -44.67% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -24.14% |
| 2021 | -28.71% |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...